Amneal Pharmaceuticals Q3 revenue comes in at $863M, up 10%
Pontos principais
- Amneal Pharmaceuticals reported third-quarter 2026 revenue of $863 million, up 10%, while recording a net loss of $22 million.
- Adjusted earnings increased 53% to $0.26 per share, beating analysts' estimates, while adjusted EBITDA rose 30% to $207 million.
- Amneal raised its full-year revenue forecast to $3.15 billion–$3.25 billion but lowered operating cash flow guidance to $325 million–$375 million.
Amneal Pharmaceuticals (NASDAQ:AMRX) reported third-quarter 2026 revenue of $863 million, up 10%, while posting a $22 million net loss.
Revenue increased from $785 million a year earlier, although earnings shifted from a $0.01 per-share profit to a $0.06 loss.
Adjusted EBITDA rose 30% to $207 million, while adjusted earnings increased 53% to $0.26 per share, supported by higher sales and gross profit.
Amneal raised its 2026 revenue forecast to $3.15 billion–$3.25 billion but reduced its operating cash flow outlook to $325 million–$375 million.
Affordable Medicines revenue increased 19% and Specialty grew 20%, while AvKARE revenue declined 17% following a prior-year cardiovascular product launch.
Nine-month operating cash flow fell to $50.3 million from $209.7 million, while the company continued integrating Kashiv and expanding its biosimilar portfolio.
-640x360.webp&w=3840&q=75)
